Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
Rodriguez-Mogeda C, van Lierop ZYGJ, van der Pol SMA, Coenen L, Hogenboom L, Kamermans A, Rodriguez E, van Horssen J, van Kempen ZLE, Uitdehaag BMJ, Teunissen CE, Witte ME, Killestein J, de Vries HE.
Rodriguez-Mogeda C, et al. Among authors: de vries he.
J Neuroinflammation. 2023 Sep 26;20(1):215. doi: 10.1186/s12974-023-02900-z.
J Neuroinflammation. 2023.
PMID: 37752582
Free PMC article.